Printer Friendly

BUTORPHANOL TARTRATE NASAL SPRAY OFFERS CONVENIENT THERAPY FOR TREATING MIGRAINE PAIN

 PRINCETON, N.J., March 24 /PRNewswire/ -- Migraine headache is a debilitating condition that affects 11 million Americans.
 Migraine headaches are recurrent and may occur as frequently as several times per month. It is estimated that 64 million work days are lost annually as a result of the devastating pain of migraine.
 Despite the wide variety of products used in migraine treatment, few migraine sufferers have experienced satisfactory relief from the available therapies.
 With the recent introduction of Imitrex(R) (sumatriptan) by Glaxo Pharmaceuticals and the earlier launch of Stadol(R) NS(TM) (butorphanol tartrate nasal spray) by Mead Johnson Laboratories, physicians have two new and unique drug therapies with which to treat their migraine patients.
 The objective of migraine therapy is either to prevent the attack, terminate the attack or relieve the symptoms once the attack begins. Imitrex(R) (sumatriptan) works to abort the attack, while Stadol(R) NS(TM) (butorphanol tartrate nasal spray) relieves the symptomatic migraine pain. Stadol NS may be appropriate for those patients for whom sumatriptan is not effective.
 The unique route of nasal administration makes Stadol NS well suited (with appropriate medical instruction) for outpatient management of acute pain including migraine headache pain and post-surgical pain. Nasal delivery allows for rapid absorption of the drug into the systemic circulation. This absorption rate is due to the surface area of the nasal cavity and to the network of capillary vessels that line the nasal passages.
 For migraine sufferers, Stadol NS can eliminate trips to the emergency room since physicians can call pharmacies to fill prescriptions for this non federally controlled pain reliever.
 Clinical studies have shown that Stadol NS is also safe and effective in relieving:
 -- Post-surgical pain following general abdominal surgery;
 -- Pain following cesarean section and hysterectomy; and
 -- Post-partum pain following episiotomy.
 Stadol NS has been shown in clinical trials to produce onset of pain relief within 15 minutes after a single 1 mg dose (one spray in one nostril). A second dose (an additional spray in the other nostril) can be taken within 60 to 9O minutes if needed. One dose of Stadol NS can provide relief for four to five hours.
 First introduced in U.S. clinical practice in 1978 as an injectable drug, butorphanol tartrate has shown low abuse potential in more than 15 years of use as a potent analgesic. For this reason, several key agencies -- including the World Health Organization, the U.S. Drug Enforcement Administration, and the U.S. Food and Drug Administration (FDA) -- concur that neither Stadol(R) NS(TM) (butorphanol tartrate nasal spray) nor Stadol(R) injectable require restricted prescribing and dispensing as federally controlled substances.
 The most commonly seen side effect with Stadol NS is somnolence (sedation). Other side effects include dizziness and nausea and/or vomiting. It is recommended that patients not drive or perform potentially hazardous tasks while using the drug.
 Available by prescription only, Stadol NS is a synthetically derived opioid analgesic with sedative properties that relieves acute pain. As a recent addition to the available migraine therapies, Stadol NS offers patients the potency of a narcotic analgesic but with minimal potential for addiction. As a nasal spray, Stadol NS is a convenient dosage form for acute pain management following outpatient procedures such as tubal ligation, laparoscopy, laparotomy, and invasive surgical procedures such as hysterectomy, cesarean section and general abdominal procedures. Stadol NS is marketed by Mead Johnson Laboratories, a Bristol-Myers Squibb (NYSE: BMY) company.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non prescription medicines.
 /delval/
 -0- 3/24/93
 /CONTACT: Patrick Donohue of Bristol Myers Squibb, 609-252-5685, or Chilton G. Goebel Jr., APR, of Harris, Baio & McCullough, 215-440-9800, for Mead Johnson Laboratories/
 (BMY)


CO: Mead Johnson Laboratories; Bristol-Myers Squibb ST: New Jersey IN: MTC SU: PDT

MP-LJ -- PH003 -- 9033 03/24/93 10:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 24, 1993
Words:667
Previous Article:NATIONAL STEEL PRICES INITIAL PUBLIC OFFERING
Next Article:CELLULAR TELEPHONES CAN HELP HOOPS JUNKIES GET THROUGH MARCH MADNESS
Topics:


Related Articles
FDA APPROVES BRISTOL-MYERS SQUIBB'S STADOL NS NEW PRESCRIPTION NASAL SPRAY ANALGESIC
UNIQUE NEW NASAL SPRAY FORM OF STADOL(R) ENTERS PRESCRIPTION PAIN RELIEF MARKET
NAUSEA REDUCED IN MIGRAINE PATIENTS FOLLOWING ADMINISTRATION OF DHE-45, STUDY SHOWS
IMITREX(R) TABLETS NOW AVAILABLE FOR PEOPLE WITH MIGRAINE IN THE U.S. FIRST HIGHLY SELECTIVE MIGRAINE THERAPY IN TABLET FORM
Imitrex(R) Nasal Spray Now Available for People With Migraine in the U.S.
Novartis Pharmaceuticals Corporation Receives FDA Clearance to Market Migranal(R) (dihydroergotamine mesylate, USP) Nasal Spray
Migranal(R) Nasal Spray Now Available to Treat Migraine Headaches
Amerge (naratriptan hydrochloride) Tablets Now Available To People with Migraine in the U.S.
Studies Show Imitrex Provides Fast, Consistent Relief For Migraine Sufferers
Imitrex Injection And Tablets Proven Effective In Difficult-To-Treat Menstrually-Associated Migraine

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters